{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Halofuginone_Hydrobromide",
  "nciThesaurus": {
    "casRegistry": "17395-31-2",
    "chebiId": "",
    "chemicalFormula": "C16H17BrClN3O3.BrH",
    "definition": "The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.",
    "fdaUniiCode": "PTC2969MV1",
    "identifier": "C2656",
    "preferredName": "Halofuginone Hydrobromide",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1971"
    ],
    "synonyms": [
      "HALOFUGINONE HYDROBROMIDE",
      "Halofuginone Hydrobromide",
      "Halofuginone IV (intravenous)",
      "Halofuginone hydrobromide",
      "RU 19110",
      "Tempostatin",
      "halofuginone hydrobromide"
    ]
  }
}